OncoMatch/Clinical Trials/NCT06532617

Cadonilimab Combined With S-1 or Capecitabine as Second-line Treatment for Advanced Pancreatic Cancer

Is NCT06532617 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Cadonilimab+S-1or Capecitabine for pancreatic neoplasms.

Phase 2RecruitingShanghai General Hospital, Shanghai Jiao Tong University School of MedicineNCT06532617Data as of May 2026

Treatment: Cadonilimab+S-1or Capecitabine — This is a single arm, single cencer, phase II clinical trial. This study aims to evaluate the efficacy and safety of Cadonilimab combined with S-1 or capecitabine as a second-line treatment for advanced pancreatic cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Pancreatic Cancer

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Min 1 prior line

Must have received: anti-tumor treatment — first-line

previously received standard first-line anti-tumor treatment (radiotherapy, chemotherapy, targeted or immunotherapy, etc.)

Lab requirements

Blood counts

adequate organ function

Kidney function

adequate organ function

Liver function

adequate organ function

Adequate organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify